Stay Up
to Date
Stay Up
to Date
Breaking News,
Updates, & More
Breaking News,
Updates, & More
Click Here to
Subscribe
Click Here to
Subscribe

Opdivo plus Yervoy and Chemotherapy Approved as First-Line Therapy for Metastatic NSCLC, Regardless of PD-L1 Expression

Web Exclusives - FDA Updates, Lung Cancer

On May 26, 2020, the FDA approved a new indication for the combination of the PD-1 inhibitor nivolumab (Opdivo; Bristol Myers Squibb) and the CTLA-4 inhibitor ipilimumab (Yervoy; Bristol Myers Squibb) plus 2 chemotherapy cycles for the first-line treatment of patients with recurrent or metastatic non–small-cell lung cancer (NSCLC), including patients with squamous or nonsquamous NSCLC, regardless of PD-L1 expression, and no EGFR or ALK genomic aberrations. Nivolumab plus ipilimumab may offer a synergistic mechanism of action of 2 types of immune checkpoint inhibitors—PD-1 and CTLA-4 inhibitors.

This new approval comes on the heels of the May 15, 2020, approval of nivolumab plus ipilimumab for the first-line treatment of patients with metastatic NSCLC whose tumors express PD-L1 ≥1% and have no EGFR or ALK genomic aberrations. The new approval represents the sixth indication for the combination of nivolumab plus ipilimumab across 5 types of cancer.

“We have come a long way in understanding the role of dual immunotherapy-based approaches in cancer and the potential impact on patients’ long-term outcomes,” said David P. Carbone, MD, PhD, study investigator and Director of the James Thoracic Oncology Center, Ohio State University. “The positive findings from CheckMate-9LA demonstrate the benefit of combining dual immunotherapy with limited chemotherapy for NSCLC patients regardless of PD-L1 status.”

“Receiving a diagnosis of advanced lung cancer is devastating,” said Andrea Ferris, President and Chief Executive Officer of LUNGevity. “Today’s announcement is welcome news as it provides a new dual immunotherapy-based option for previously untreated patients searching for a treatment that may help extend their lives.”

The FDA approved this new indication for nivolumab plus ipilimumab and limited chemotherapy based on the results of the CheckMate-9LA phase 3 clinical trial, a randomized, open-label, multicenter study. The study included patients with metastatic or recurrent NSCLC regardless of PD-L1 expression who received either nivolumab plus ipilimumab and 2 cycles of platinum-doublet chemotherapy (N = 361) or 4 cycles of platinum-doublet chemotherapy followed by optional pemetrexed maintenance therapy if eligible (N = 358), for up to 2 years, or until disease progression or unacceptable toxicity.

The primary end point was overall survival (OS). The secondary efficacy outcomes included progression-free survival, overall response rate (ORR), and duration of response, as assessed by blinded independent central review.

The approval of 360 mg of nivolumab plus 1 mg/kg of ipilimumab with limited chemotherapy for this indication was based on the results of the prespecified interim analysis from the CheckMate-9LA study, which showed that nivolumab plus ipilimumab and 2 cycles of platinum-doublet chemotherapy had superior OS versus chemotherapy (P = .0006), regardless of PD-L1 expression or tumor histology. The median OS was 14.1 months (95% confidence interval [CI], 13.2-16.2) versus 10.7 months (95% CI, 9.5-12.5), respectively.

The ORR was 38% (95% CI, 33-43) with nivolumab plus ipilimumab and limited chemotherapy versus 25% (95% CI, 21-30) with chemotherapy alone. At 12.7 months, the median OS was 15.6 months (95% CI, 13.9-20.0) versus 10.9 months (95% CI, 9.5-12.5), respectively. Furthermore, at 1 year, 63% of patients who received the combination therapy plus limited chemotherapy versus 47% of those who received chemotherapy alone were still alive.

As with all immunotherapies, nivolumab and ipilimumab are associated with immune-mediated adverse events. The most common (>2%) serious adverse events with nivolumab and ipilimumab in combination with platinum-doublet chemotherapy were pneumonia, diarrhea, febrile neutropenia, anemia, acute kidney injury, musculoskeletal pain, dyspnea, pneumonitis, and respiratory failure.

Serious adverse reactions were reported in 57% of the patients who received the immunotherapy combination with limited chemotherapy; 24% of patients discontinued treatment because of adverse events, and 56% of patients had at least 1 treatment withheld because of side effects. Fatal adverse reactions occurred in 7 (2%) patients.

Related Items
Gavreto, RET Inhibitor, FDA Approved for Metastatic NSCLC with RET Fusions
Web Exclusives published on November 16, 2020 in FDA Updates
Rearrangement During Transfection (RET) Fusions and Their Role as Oncogenic Drivers
Web Exclusives published on September 16, 2020 in Lung Cancer
Molecular Profiling Is Critical for Optimizing NSCLC Therapy
Web Exclusives published on September 16, 2020 in Lung Cancer
Response to Immune Checkpoint Inhibitors Among Patients with NSCLC with RET Rearrangements
Web Exclusives published on September 16, 2020 in Lung Cancer
Clinical Trials of Targeted Therapies in RET-Rearranged NSCLC
Web Exclusives published on September 16, 2020 in Lung Cancer
Unmet Needs in NSCLC
Web Exclusives published on September 16, 2020 in Lung Cancer
FDA News TON August 2020
TON - August 2020, Vol 13, No 4 published on August 14, 2020 in FDA Updates
Durvalumab plus Chemotherapy Improves Overall Survival in Extensive-Stage Small-Cell Lung Cancer
Patricia Stewart
TON - August 2020, Vol 13, No 4 published on August 14, 2020 in Lung Cancer
Capmatinib Shows Promise in MET-Amplified Non–Small- Cell Lung Cancer
William King
TON - August 2020, Vol 13, No 4 published on August 14, 2020 in Lung Cancer
Zepzelca New Therapy Approved for Metastatic Small-Cell Lung Cancer
Web Exclusives published on June 22, 2020 in FDA Updates, Lung Cancer
Last modified: June 2, 2020